

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

### Multiple Technology Appraisal

#### Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520]

#### Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Dova Pharmaceuticals (avatrombopag)</li> <li>• Shionogi Inc (lusutrombopag)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action on Addiction</li> <li>• Addaction</li> <li>• Addiction Today</li> <li>• ADFAM</li> <li>• Alcohol Concern</li> <li>• British Liver Trust</li> <li>• Compass UK</li> <li>• Haemophilia Society</li> <li>• Hepatitis B Foundation UK</li> <li>• Hepatitis C Trust</li> <li>• ITP Support Association</li> <li>• Lifeline Project</li> <li>• Liver4Life</li> <li>• Muslim Council of Great Britain</li> <li>• National Obesity Forum</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Turning Point</li> <li>• Weight Concern</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association for the Study of the Liver</li> <li>• British Blood Transfusion Society</li> <li>• British Committee for Standards in Haematology</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Hepato-Biliary Group</li> <li>• Cochrane Infectious Diseases group</li> <li>• Foundation for Liver Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• UK National Screening Committee</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> </ul>

Final matrix for the technology appraisal of avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure ID1520

Issue date: November 2018

© National Institute for Health and Care Excellence 2018. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• British Geriatric Society</li> <li>• British Infection Society</li> <li>• British Society for Haematology</li> <li>• British Viral Hepatitis Group</li> <li>• Hepatitis Nurse Specialist Forum</li> <li>• Haemophilia Nurses Association</li> <li>• NHS Blood and Transplant</li> <li>• Positive Prevention Plus</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Clinical Virology Network</li> <li>• UK Forum on Haemoglobin Disorders</li> <li>• UK Haemophilia Centre Doctors' Organisation</li> <li>• UK Harm Reduction Alliance</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS Coventry and Rugby CCG</li> <li>• NHS England</li> <li>• NHS Leeds North CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.